Author Archives: Maria Verissimo, MSc

Deflazacort Preserves Muscular Function Longer in Duchenne Muscular Dystrophy Patients than Other Treatments

Deflazacort delays loss of ambulation (LOA) in Duchenne muscular dystrophy (DMD) patients by an average of 3.8 years more than standard of care corticosteroid treatments prednisone/prednisolone, post-hoc analyses of a Phase 3 clinical trial found. The new conclusions follow a reassessment of data obtained in the placebo group of the completed ACT DMD clinical trial (NCT01826487). The goal…